top of page


Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.

nuaxia
6 hours ago2 min read


European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer
The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.

nuaxia
6 hours ago2 min read


Oxford BioDynamics signs first pharmaceutical EpiSwitch Orion agreement with Johnson & Johnson
Oxford BioDynamics has secured its first pharmaceutical-company agreement for the EpiSwitch Orion platform, partnering with Johnson & Johnson on inflammatory bowel disease biomarker discovery.

nuaxia
Nov 62 min read


FDA approves Lyrfigtu for previously treated FGFR2-altered cholangiocarcinoma
The FDA has approved Lyrfigtu for adults with previously treated FGFR2-altered cholangiocarcinoma, adding a new targeted therapy for this molecularly defined group of bile duct cancers.

nuaxia
Sep 241 min read


Renalytix and Quest Diagnostics partner to expand kidneyintelX.dkd testing across the US
Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test for patients with type 2 diabetes and chronic kidney disease.

nuaxia
Sep 21 min read


McKesson agrees $2.25 billion acquisition of Precision Medicine Group to expand biopharma services
The acquisition adds clinical research, biomarker, laboratory, market access and commercialisation capabilities to McKesson’s Oncology & Multispecialty business, extending its services across the drug-development pathway.

nuaxia
Aug 262 min read


HanchorBio partners with Taiwan Cancer Moonshot team to advance precision immunotherapy development
The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.

nuaxia
Aug 132 min read
bottom of page